Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00975533 |
Recruitment Status : Unknown
Verified September 2009 by Chinese University of Hong Kong.
Recruitment status was: Not yet recruiting
First Posted : September 11, 2009
Last Update Posted : September 11, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetes Mellitus | Device: Tantalus Drug: Insulin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Study to Evaluate the Efficacy and Acceptability of Laparoscopic Placement of Gastric Modulator (TANTALUS® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients Sub-optimally Controlled With Oral Anti-diabetic Agents. |
Study Start Date : | October 2009 |
Estimated Primary Completion Date : | July 2011 |
Estimated Study Completion Date : | October 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Tantalus
The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
|
Device: Tantalus
The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. |
Active Comparator: Control
Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
|
Drug: Insulin
Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis. |
- changes in body weight before and after interventions at 6 and 12 months [ Time Frame: 6 months and 1 year ]
- changes in HbA1c before and after interventions [ Time Frame: 6 and 12 months ]
- frequency of hypoglycaemia [ Time Frame: 6 month and 1 year ]
- dichotomous composite end point assessing the proportion of patients meeting all of the following prespecified criteria defined as: 1. HbA1c ≤7.0% or an HbA1c reduction from baseline ≥0.5% 2. no weight gain 3. no severe hypoglycaemia [ Time Frame: 6 and 12 months ]
- composite quantitative score calculate from the results of glycemic control, weight response and degree of hypoglycemia [ Time Frame: 6 month and 1 year ]
- waist circumferences [ Time Frame: 6 month and 1 year ]
- insulin secretory responses (as measured by the standard meal test) [ Time Frame: 6 month and 1 year ]
- Hormonal profiles (including gut hormones) [ Time Frame: 6 months and 1 year ]
- a. eating behavior, satiety and quality of life as measured by the Food Frequency Questionnaire, Visual Analogue Rating Scale To Assess Satiety, EDE, SF-36 and GIQOL questionnaires [ Time Frame: 6 month and 1 year ]
- resting energy expenditure as monitored by indirect calorimetry (MedGem). [ Time Frame: 6 month and 1 year ]
- radiological assessment (ultrasound scan and densitometry to measure mesenteric and total body fat respectively) [ Time Frame: 6 months and 1 year ]
- differences in insulin requirement [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Able to provide written informed consent
- Adult patients aged between 18 and 60 years (inclusive)
- Male or female of Chinese ethnicity
- Type 2 diabetes mellitus with disease duration of greater than 2 and less than 10 years
- severe obesity, includes BMI 25 to 27.5 kg/m and central obesity defined by waist circumference greater than 90 cm in women and greater than 95 in men, or BMI greater than 27.5 to less than 35 kg/m
- HbA1c greater than or equals to 7.5% but less than 10% despite treated with maximum dose or maximally tolerated dose of 2 anti-diabetic drugs (OAD) with good drug compliance
Exclusion Criteria:
- On anti-obesity drugs
- On insulin treatment at the time of the recruitment
- On glitazone or incretins (dipeptidyl peptidase-4 inhibitor or glucagons-like peptide-1) treatment
- On any implantable device including cardiac pacing
- Anticipated to have MRI examinations
- Fasting C-peptide level less than 0.5g/L
- Renal impairment (defined as serum creatinine greater than 150mol/L and/or estimated glomerular filtration rate less than 60 mL/min/1.73m)
- Significant liver impairment (ALT more than 3 times upper limit of normal range)
- Active malignant disease. Patients with malignant disease who have been disease-free for at least 5 years are eligible
- Active infection
- Active and uncontrolled thyroid diseases
- Childbearing age female patients without reliable contraceptive methods
- Life expectancy less than 12 months
- Administration of another investigational drugs or procedures within 4 weeks before screening
- Any medical illness or condition as judged by the investigators as ineligible to participate the study
- Special population, e.g. prisoner, mentally disabled, investigators' student or employees

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00975533
Contact: Simon KH Wong, MBChB | 852-26322627 | wongkhmo@cuhk.edu.hk |
China, Hong Kong | |
Prince of Wales Hospital | |
Shatin, Hong Kong, China | |
Principal Investigator: Simon KH Wong, MBChB | |
Sub-Investigator: Alice PS Kong, MBChB | |
Sub-Investigator: Ronald CW Ma, MBChB | |
Sub-Investigator: Juliana CN Chan, MBBS | |
Sub-Investigator: Enders KW Ng, MBChB | |
Sub-Investigator: Vannessa WS Ng, MBChB | |
Sub-Investigator: Francis CC Chow, MBBS | |
Sub-Investigator: Wing Yee So, MBChB | |
Sub-Investigator: Winnie CW Chu, MBChB |
Principal Investigator: | Simon KH Wong, MBChB | Chinese University of Hong Kong |
Responsible Party: | Simon Kin-Hung WONG, The Chinese University of Hong Kong |
ClinicalTrials.gov Identifier: | NCT00975533 |
Other Study ID Numbers: |
CRE-2008.335 |
First Posted: | September 11, 2009 Key Record Dates |
Last Update Posted: | September 11, 2009 |
Last Verified: | September 2009 |
type 2 diabetes mellitus obesity |
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs |